Ranibizumab for diabetic retinopathy

Current Diabetes Reviews

Volumn 5, Issue 1, 2009, Pages 47-51

  Rodriguez Fontal, Monica ^a   Alfaro, Virgil ^a   Kerrison, John B ^a   Jablon, Eric P ^a  

^a Charleston Neuroscience Institute   (United States)

Author keywords

Diabetes; Lucentis; Macular edema; Ranibizumab; Retinopathy

Indexed keywords

BEVACIZUMAB; IMMUNOGLOBULIN F(AB) FRAGMENT; ISOPROTEIN; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

BINDING AFFINITY; CLINICAL TRIAL; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; LASER COAGULATION; NEOVASCULAR GLAUCOMA; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOGENESIS; PILOT STUDY; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; VISUAL IMPAIRMENT; ANIMAL; DEVELOPING COUNTRY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; PATHOLOGY; PATHOPHYSIOLOGY; RETINA; RETINA BLOOD VESSEL; RETINA MACULA EDEMA;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DEVELOPING COUNTRIES; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; HUMANS; MACULAR EDEMA; RETINA; RETINAL VESSELS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 65549105817     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339909787314239     Document Type: Review

References (22)

1. Aiello LP. Angiogenic pathways in diabetic retinopathy. N Engl J Med 2005; 353: 839-41.
2. Neubauer AS, Kook D, Haritoglou C, et al. Bevacizumab and retinal ischemia. Ophthalmology 2007; 114: 2096.
3. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, et al. for the Pan American Collaborative Retina Group. Twelve-month safety of intravitreal injections of bevacizumab (Avastin(R)): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2007.
4. Bresnick GH. Diabetic macula edema: a review. A critical review highlighting diffuse macular edema. Ophthalmology 1983; 90: 1301-17.
5. Bresnick GH. Diabetic macular edema. A review. Ophthalmology 1986; 93: 989-97.
6. Moore J, Bagley S, Ireland G, McLeod D, Boulton M. Three dimensional analysis of microaneurysms in the human diabetic retina. J Anat 1999; 194: 89-100.
7. Nguyen QD, Shah SM, Van Anden E, Sung JU, Vitale S, Campochiaro PA. Supplemental oxygen improves diabetic macular edema: a pilot study. Invest Ophthalmol Vis Sci 2004; 45: 617-24.
8. Malecaze F, Clamens S, Simorre-Pinatel V, et al. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 1994; 112: 1476-82.
9. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-7.
10. Aiello LM, Cavallerano J. Diabetic retinopathy. Curr Ther Endocrinol Metab 1997; 6: 475-85.
11. Vinores SA, Youssri AI, Luna JD, et al. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol Histopathol 1997; 12: 99-109.
12. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 1999; 274: 23463-7.
13. Joussen AM, Murata T, Tsujikawa A, et al. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 2001; 158: 147-52.
14. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996; 103: 1820-8.
15. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445-50.
16. Funatsu H, Yamashita H, Noma H, et al. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol 2005; 243: 3-8.
17. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005; 46: 726-33.
18. Gaudreault Reich M, Arata A, Rusi J, Pelletie N, Shiu V. Ocular Pharmacokinetics and Antipermeability Effect of rhuFab V2 in Animals. ARVO 2003. Poster B645.
19. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114: 2179-82.
20. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006; 113: 1706-12.
21. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006; 142: 961-9.
22. Adamis AP, Altaweel M, Bressler NM, et al. Macugen Diabetic Retinopathy Study Group. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006; 113: 23-8.